Lemtrada Panel Review Pivots On What Constitutes An Adequate, Well-Controlled Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will be asked whether open-label, rater-blinded trials meet approval standards for Sanofi/Genzyme’s Lemtrada sBLA; agency reviewers say no.